Skip to main content
. 2018 Oct 25;47(2):641–652. doi: 10.1177/0300060518807100

Figure 2.

Figure 2.

Comparison of disease-free survival between Han (n=236) and Zhuang women (n=101) with hormone receptor-positive breast cancer treated with oral tamoxifen 20 mg daily and ovarian function suppression with subcutaneous injection of leuprorelin 3.75 mg every 28 days.